Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel ...

A recent study on the application of Metagenomic next-generation sequencing (mNGS) found that mNGS can achieve early detection of pathogens and accelerate the development of targeted anti-infection ...

Next-generation sequencing (NGS) has transformed genomic research and clinical diagnostics by enabling rapid, high-throughput analysis of genetic material. The application of NGS to formalin-fixed ...

Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the range of conditions that can be identified at birth. Next-generation ...

Quest expects the new blood test will support response monitoring in clinical trials.

Bulk harvest release testing for adventitious viruses is an integral part of biosafety for manufacturing biopharma products. Finding a testing strategy that works for diverse biologics modalities ...

Opportunities in the Next Generation Cancer Diagnostics Market include leveraging advancements in genomic and proteomic ...

Patients with multiple CALMs w/wo skinfold freckling and no other typical NF1 associated features (Lisch nodules, bone abnormalities, neurofibromas, optic pathway gliomas). The DNA-based ...

Located on the Buffalo Niagara Medical Campus and the first next-generation sequencing service provider in the region, UB's Genomics and Bioinformatics Core Facility provides high-quality services ...

Patients with classic NF1 including the presence of cutaneous neurofibromas or Lisch nodules, as no genetic heterogeneity demonstrated so far associated with this phenotype. The NF1-only by NGS ...